Melissa Studnicka, NP
Primary Care · Kearney, NENPI 1891148789
Payments from drug & device makers
What this record shows
10 manufacturers reported payments, led by Integra Lifesciences Corporation at 45.8% of the total. Reporting peaked in 2024 at $553 and has fallen 59.5% since, to $224 in 2025.
Across 30 payments — averaging $31.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$439
- Smith+Nephew$149
- Medline Industries LP$91
- Organogenesis Inc.$87
- Solventum Corporation$56
- Kerecis Limited$56
- plus $80 from 4 others
What the payments were for
- Food & beverage$54957%
- Other$40943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integra Lifesciences Corporation | 3 | $439 |
| Smith+Nephew | 9 | $149 |
| Medline Industries LP | 4 | $91 |
| Organogenesis Inc. | 5 | $87 |
| Solventum Corporation | 3 | $56 |
| Kerecis Limited | 2 | $56 |
| Polynovo North America LLC | 1 | $32 |
| AbbVie | 1 | $18 |
| KCI USA, Inc. | 1 | $16 |
| Convatec Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACell$409
How this compares
$958 in reported general payments places this provider in the 70th percentile of 65 primary care providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $1,337 |
| Doxycycline Hyclate | 22 | $248 |
| Cephalexin | 12 | $93 |
Paid to pharmacies, not to this prescriber.
Other primary care in Kearney
- Diane JacksonKearney$51
- Jenna KoppOmaha$141K
- Alexis BarbosaOmaha$7K
- Rabia MoukradOmaha$6K
- Lisa BruhaOrd$5K
- Laurel DubaLincoln$5K
- Kerry Takedala Vista$4K
- Kasee WiesenFremont$3K
- Amy ArndtLincoln$2K
- Keri DillonOmaha$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.